ABIONYX Pharma Yönetim

Yönetim kriter kontrolleri 4/4

ABIONYX Pharma CEO'su Cyrille Tupin, Sep2019 tarihinde atandı, in görev süresi 5.17 yıldır. in toplam yıllık tazminatı € 278.85K olup, şirket hissesi ve opsiyonları dahil olmak üzere 79.1% maaş ve 20.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 4.59% ine doğrudan sahiptir ve bu hisseler € 1.94M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.2 yıl ve 8.5 yıldır.

Anahtar bilgiler

Cyrille Tupin

İcra Kurulu Başkanı

€278.8k

Toplam tazminat

CEO maaş yüzdesi	79.1%
CEO görev süresi	5.2yrs
CEO sahipliği	4.6%
Yönetim ortalama görev süresi	5.2yrs
Yönetim Kurulu ortalama görev süresi	8.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Cyrille Tupin'un ücretlendirmesi ABIONYX Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-€3m
Mar 31 2024	n/a	n/a	-€3m
Dec 31 2023	€279k	€221k	-€4m
Sep 30 2023	n/a	n/a	-€4m
Jun 30 2023	n/a	n/a	-€4m
Mar 31 2023	n/a	n/a	-€4m
Dec 31 2022	€289k	€210k	-€4m
Sep 30 2022	n/a	n/a	-€5m
Jun 30 2022	n/a	n/a	-€6m
Mar 31 2022	n/a	n/a	-€6m
Dec 31 2021	€649k	€200k	-€6m
Sep 30 2021	n/a	n/a	-€5m
Jun 30 2021	n/a	n/a	-€4m
Mar 31 2021	n/a	n/a	-€3m
Dec 31 2020	€711k	€200k	-€2m
Sep 30 2020	n/a	n/a	-€2m
Jun 30 2020	n/a	n/a	-€2m
Mar 31 2020	n/a	n/a	-€59k
Dec 31 2019	n/a	n/a	€2m
Sep 30 2019	n/a	n/a	€925k
Jun 30 2019	n/a	n/a	€1k
Mar 31 2019	n/a	n/a	-€3m
Dec 31 2018	€5m	€175k	-€6m

Tazminat ve Piyasa: Cyrille 'ın toplam tazminatı ($USD 290.38K ) UK pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 354.22K ).

Tazminat ve Kazançlar: Cyrille 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Cyrille Tupin (48 yo)

5.2yrs

Görev süresi

€278,848

Tazminat

Sir Cyrille Tupin, CPA is Chief Executive Officer, General Manager and Director at ABIONYX Pharma SA since September 6, 2019. Mr. Tupin served as the Chief Financial and Administrative Officer at ABIONYX...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Cyrille Tupin	CEO, GM & Director	5.2yrs	€278.85k	4.59% € 1.9m
Christian Chavy	Independent Director	5.8yrs	€29.25k	Veri yok
Emmanuel Fougeroux	Administrative & Financial Director	no data	Veri yok	Veri yok
Constance Peyrottes	Vice President of Clinical	no data	Veri yok	Veri yok
Robert Andrew Scott	Chief Medical Officer and Head of R&D	less than a year	Veri yok	Veri yok
Laurent Guerci	Chief Digital & Innovation Officer	no data	Veri yok	Veri yok

5.2yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim: 0RAG 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Cyrille Tupin	CEO, GM & Director	5.2yrs	€278.85k	4.59% € 1.9m
Christian Chavy	Independent Director	9.8yrs	€29.25k	Veri yok
Olivier Martinez	Censor	9.8yrs	Veri yok	Veri yok
Michael Davidson	Chairman of Scientific Advisory Board	no data	€23.00k	Veri yok
Karen Noël	Independent Director	7.4yrs	€29.25k	Veri yok
Laura Coruzzi	Independent Director	9.5yrs	€18.75k	Veri yok
Emmanuel Huynh	Chairman of the Board	5.3yrs	€22.05k	12.54% € 5.3m

8.5yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0RAG 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.5 yıldır).

ABIONYX Pharma Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

ABIONYX Pharma SA, Annual General Meeting, Jun 27, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D

ABIONYX Pharma SA, Annual General Meeting, Jun 28, 2023

Recent updates

ABIONYX Pharma RACERS Study Clinical Results in Brain-Fog Selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting Kidney Week

First half 2024 earnings released

ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis

ABIONYX Pharma SA, Annual General Meeting, Jun 27, 2024

ABIONYX Pharma SA to Report Q2, 2024 Results on Aug 22, 2024

Insufficient new directors

Insufficient new directors

New minor risk - Revenue size

Full year 2023 earnings released

ABIONYX Pharma SA to Report Q2, 2024 Results on Sep 26, 2024

Insufficient new directors

ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring’S Human-Plasma-Derived Apoa-I, CSL112

ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D

ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023

ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I

Abionyx Pharma Racers Study Data in Sepsis Presented At the American Society of Nephrology (Asn) 2023 Annual Meeting "Kidney Week"

New minor risk - Share price stability

ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology 2023 Annual Meeting " Kidney Week"

First half 2023 earnings released

New minor risk - Shareholder dilution

ABIONYX Pharma Successfully Manufactures a Second Batch of Recombinant Human ApoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess

New major risk - Revenue and earnings growth

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma SA, Annual General Meeting, Jun 28, 2023

ABIONYX Pharma SA to Report Q2, 2023 Results on Aug 17, 2023

ABIONYX Pharma Announces Successful Manufacturing of the First Batch of CER-001 with Recombinant Human ApoA-I Using aNew Innovative and Robust Industrial Bioprocess

Full year 2022 earnings released

ABIONYX Pharma Reports Positive Results from Phase 2A Pilot Clinical Trial

ABIONYX Pharma SA to Report Fiscal Year 2022 Results on Apr 27, 2023

Insufficient new directors

Insufficient new directors

Insufficient new directors

ABIONYX Pharma SA Announces Final Patient Enrollment in Phase 2a Clinical Trial with CER-001, Bio-HDL for the Treatment of Patients with Sepsis at High Risk of Developing Acute Kidney Injury

Insufficient new directors

First half 2022 earnings released

ABIONYX Pharma Reports Positive Interim Results from Phase 2A Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients At High Risk of Developing Acute Kidney Injury

ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease

ABIONYX Pharma SA to Report First Half, 2022 Results on Sep 29, 2022

ABIONYX Pharma Announces That the French Drug Safety Agency Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease

ABIONYX Announces First Patient Enrolled in Phase 2a Clinical Study With CER-001, the Bio-HDL for the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

Investor sentiment improved over the past week

ABIONYX Announces Positive Clinical Results From CER-001 in an Ultrarare Kidney Disease Published in the Annals of Internal Medicine

ABIONYX Pharma SA to Report First Half, 2021 Results on Sep 09, 2021

ABIONYX Pharma SA Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury

ABIONYX Pharma Announces Publication of Pre-Clinical Data in the Journal Metabolism Demonstrating CER-001 Improves Lipid Profile and Kidney Function for an Ultra-Rare Kidney Disease

ABIONYX Pharma Announces the Observation of Positive Therapeutic Signals in Temporary Authorizations for Use (ATUn) in France and Italy for an Ultra-Rare Kidney Disease

ABIONYX Pharma SA announced that it expects to receive €1.859997 million in funding from Domundi SC and other investors

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş